Development and characterisation of ursolic acid nanocrystals without stabiliser having improved dissolution rate and in vitro anticancer activity

AAPS PharmSciTech

Volumn 15, Issue 1, 2014, Pages 11-19

  Song, Ju ^a   Wang, Yancai ^a,b   Song, Yuelin ^a   Chan, Hokman ^a   Bi, Chao ^a   Yang, Xiao ^a   Yan, Ru ^a   Wang, Yitao ^a   Zheng, Ying ^a  

^a University of Macau   (Macao)

^b SHANDONG POLYTECHNIC UNIVERSITY   (China)

Author keywords

anticancer; dissolution; MCF 7; nanocrystals; ursolic acid

Indexed keywords

ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL DIVISION; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; G2 PHASE; HUMANS; MCF-7 CELLS; NANOPARTICLES; PARTICLE SIZE; SOLUBILITY; SOLVENTS; SUSPENSIONS; TRITERPENES; WATER;

EID: 84893752875     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-0028-0     Document Type: Article

References (36)

1. Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol. 1995;49:57-68.
2. Achiwa Y, Hasegawa K, Udagawa Y. Regulation of the phosphatidylinositol 3-kinase-Akt and the mitogen-activated protein kinase pathways by ursolic acid in human endometrial cancer cells. Biosci, Biotechnol, Biochem. 2007;71:31-7.
3. Kassi E, Sourlingas TG, Spiliotaki M, Papoutsi Z, Pratsinis H, Aligiannis N, et al. Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells. Cancer Invest. 2009;27:723-33.
4. Zheng QY, Jin FS, Yao C, Zhang T, Zhang GH, Ai X. Ursolic acid-induced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells. Biochem Bioph Res Co. 2012;419:741-7.
5. Song YH, Jeong SJ, Kwon HY, Kim B, Kim SH, Yoo DY. Ursolic acid from Oldenlandia diffusa induces apoptosis via activation of caspases and phosphorylation of glycogen synthase kinase 3 beta in SK-OV-3 ovarian cancer cells. Biol Pharm Bull. 2012;35:1022-8.
6. Li J, Liang X, Yang X. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-kappaB pathways. Oncol Rep. 2012;28:501-10.
7. Huang CY, Lin CY, Tsai CW, Yin MC. Inhibition of cell proliferation, invasion and migration by ursolic acid in human lung cancer cell lines. Toxicol In Vitro. 2011;25:1274-80.
8. Xiong XJ, Chen W, Li K, Xu XQ. Study on the experiment of the poison of ursolic acid. J Yichun Med. 2001;13:54.
9. Zhou XJ, Hu XM, Yi YM, Wan J. Preparation and body distribution of freeze-dried powder of ursolic acid phospholipid nanoparticles. Drug Dev Ind Pharm. 2009;35:305-10.
10. Zhang H, Li X, Ding J, Xu H, Dai X, Hou Z, et al. Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2). Int J Pharm. 2013;441:261-8.
11. Müller RH, Gohla S, Keck CM. State of the art of nanocrystals - special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm. 2011;78:1-9.
12. Müller RH, Shegokar R, Gohla S, Keck CM. Nanocrystals: production, cellular drug delivery, current and future products. Intracell Deliver. 2011;5:411-32.
13. Junghanns JU, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed. 2008;3:295-309.
14. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62:3-16.
15. Chan HK, Kwok PC. Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliver Rev. 2011;63:406-16.
16. Li W, Das S, Ng KY, Heng PW. Formulation, biological and pharmacokinetic studies of sucrose ester-stabilized nanosuspensions of oleanolic acid. Pharm Res. 2011;28:2020-33.
17. US FDA. Bioanalytical method validationin: guidance for Industry. Silver Spring, MD: FDA; 2001.
18. de Oliveira Eloy J, Saraiva J, de Albuquerque S, Marchetti JM. Solid dispersion of ursolic acid in gelucire 50/13: a strategy to enhance drug release and trypanocidal activity. AAPS Pharmscitech. 2012;13:1436-45.
19. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliver Rev. 2011;63:456-69.
20. Zhang H, Hollis CP, Zhang Q, Li T. Preparation and antitumor study of camptothecin nanocrystals. Int J Pharm. 2011;415:293-300.
21. Jin IJ, Kim YM, Han SK. Solubilization of oleanolic acid and ursolic acid by cosolvency. Arch Pharm Res. 1997;20:269-74.
22. Zhang JY, Shen ZG, Zhong J, Hu TT, Chen JF, Ma ZQ, et al. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm. 2006;323:153-60.
23. Tong HH, Wu HB, Zheng Y, Xi J, Chow AH, Chan CK. Physical characterization of oleanolic acid nonsolvate and solvates prepared by solvent recrystallization. Int J Pharm. 2008;355:195-202.
24. Simon A, Delage C, Saux M, Chulia AJ, Najid A, Rigaucl M. Sturcture of ursolic acid ethanol solvate. Acta Crystallogr, Sect C: Cryst Struct Commun. 1992;48:726-8.
25. Ali HS, York P, Ali AM, Blagden N. Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J Control Release. 2011;149:175-81.
26. Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y, et al. Preparation of stable nitrendipine nanosuspensions using the precipitation -ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci. 2010;40:325-34.
27. Dong Y, Ng WK, Shen S, Kim S, Tan RB. Preparation and characterization of spironolactone nanoparticles by anti-solvent precipitation. Int J Pharm. 2009;375:84-8.
28. Li X, Zhen D, Lu X, Xu H, Shao Y, Xue Q, et al. Enhanced cytotoxicity and activation of ROS-dependent c-Jun NH2-terminal kinase and caspase-3 by low doses of tetrandrine-loaded nanoparticles in Lovo cells-a possible Trojan strategy against cancer. Eur J Pharm Biopharm. 2010;75:334-40.
29. Zheng D, Wang Y, Zhang D, Liu Z, Duan C, Jia L, et al. In vitro antitumor activity of silybin nanosuspension in PC-3 cells. Cancer Lett. 2011;307:158-64.
30. Qi X, Zhang D, Xu X, Feng F, Ren G, Chu Q, et al. Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line. Int J Nanomed. 2012;7:1793-804.
31. Claude B, Morin P, Lafosse M, Andre P. Evaluation of apparent formation constants of pentacyclic triterpene acids complexes with derivatized β- and γ-cyclodextrins by reversed phase liquid chromatography. J Chromatogr, A. 2004;1049:37-42.
32. Zhao F, Zhao Y, Liu Y, Chang X, Chen C, Zhao Y. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small. 2011;7:1322-37.
33. Mo L, Hou L, Guo D, Xiao X, Mao P, Yang X. Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells. Int J Pharm. 2012;436:815-24.
34. Shan JZ, Xuan YY, Zheng S, Song Q, Zhang SZ. Ursolic acid inhibits proliferation and induces apoptosis of HT-29 colon cancer cells by inhibiting the EGFR/MAPK pathway. J Zhejiang Univ Sci B. 2009;10:668-74.
35. Yu YX, Gu ZL, Yin JL, Chou WH, Kwok CY, Qin ZH, et al. Ursolic acid induces human hepatoma cell line SMMC-7721 apoptosis via p53-dependent pathway. Chinese Med J-Peking. 2010;123:1915-23.
36. Wang JS, Ren TN, Xi T. Ursolic acid induces apoptosis by suppressing the expression of FoxM1 in MCF-7 human breast cancer cells. Med Oncol. 2012;29:10-5.